Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study

BMC Endocrine Disorders

Volumn 15, Issue 1, 2015, Pages

  Umezawa, Shinichi ^a   Kubota, Akira ^a   Maeda, Hajime ^a   Kanamori, Akira ^a   Matoba, Kiyokazu ^a   Jin, Yasuyuki ^a   Minagawa, Fuyuki ^a   Obana, Mitsuo ^a   Iemitsu, Kotaro ^a   Ito, Shogo ^a   Amamiya, Hikaru ^a   Kaneshiro, Mizuki ^a   Takai, Masahiko ^a   Kaneshige, Hideaki ^a   Hoshino, Kazuhiko ^a   Ishikawa, Masashi ^a   Minami, Nobuaki ^a   Takuma, Tetsuro ^a   Sasai, Nobuo ^a   Aoyagi, Sachio ^a   Kawata, Takehiro ^a   Mokubo, Atsuko ^a   Miyairi, Yukiko ^a   Takeda, Hiroshi ^a   Honda, Shin ^a   Machimura, Hideo ^a   Motomiya, Tetsuya ^a   Waseda, Manabu ^a   Naka, Yoshikazu ^a   Tanaka, Yasushi ^b   Terauchi, Yasuo ^c   Matsuba, Ikuro ^a   more..

^a Kanagawa Physicians Association   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Elderly patients; Hypoglycemia; Sitagliptin; Sulfonylurea; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CREATININE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; JAPANESE (PEOPLE); LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; POST HOC ANALYSIS; POSTPRANDIAL STATE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT CHANGE; CHEMICALLY INDUCED; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; JAPAN; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; COHORT STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84938743389     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/s12902-015-0033-2     Document Type: Article

References (32)

1. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495-505.
2. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology. 2011;77(12):1126-34.
3. Sinclair AJ, Robert IM, Croxson SCM. Mortality in older people with diabetes mellitus. Diabet Med. 1996;14:639-47.
4. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-72.
5. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. Curr Opin Endocrinol Diabetes Obes. 2011;18:148-52.
6. Soe K, Sacerdote A, Karam J, Bahtiyar G. Management of type 2 diabetes mellitus in the elderly. Maturitas. 2011;70:151-9.
7. Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, et al. Management of type 2 diabetes in treatment-naïve elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30:3017-22.
8. Meneilly GS. Diabetes in the elderly. Med Clin North Am. 2006;90:909-23.
9. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: Causes and strategies for prevention. Drugs Aging. 2004;21:511-30.
10. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992-1019.
11. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig. 2013;4(2):108-30.
12. Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31:233-42.
13. Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs? Diab Vasc Dis Res. 2007;4(2):151-3.
14. Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049-58.
15. Round EM, Engel SS, Golm GT, Davies MJ, Kaufman KD, Goldstein BJ. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014;31:203-14.
16. Hsieh CJ, Shen FC. The durability of sitagliptin in elderly patients with type 2 diabetes. Clin Interv Aging. 2014;9:1905-11.
17. Maeda H, Kubota A, Kanamori A, Tanaka Y, Terauchi Y, Matsuba I, et al. Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7 %. J Endocrinol Invest. 2013;36(8):568-73.
18. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, ASSET-K Study group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95(1):e20-2.
19. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
20. El-Kebbi IM, Ziemer DC, Cook CB, Gallina DL, Barnes CS, Phillips LS. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care. 2004;27(2):335-9.
21. Committee on Proper Use of Incretins (GLP-1 Receptor Agonists and DPP-4 Inhibitors): [ http://www.jds.or.jp/modules/important/index.php?page=article&storyid=7 ] (in Japanese) Accessed 14 May 2015.
22. Kanamori A, Matsuba I. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer. J Clin Med Res. 2013;5(3):217-21.
23. Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Invest. 2012;3(6):503-9.
24. Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res. 2012;4(5):309-13.
25. Maeda H, Kubota A, Kanamori A, Tanaka Y, Terauchi Y, Matsuba I, et al. Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes. Diabetes Res Clin Pract. 2015. doi: 10.1016/j.diabres.2015.03.008 [Epub ahead of print]
26. Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig. 2014;5(5):475-7.
27. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595-604.
28. Yabe D, Kuwata H, Kaneko M, Ito C, Nishikino R, Murorani K, et al. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab. 2015;17(4):430-4.
29. Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166(6):983-9.
30. Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab. 2015;17(4):395-402.
31. Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. Diabetes Care. 2014;38(4):696-705.
32. Leibowitz G, Cahn A, Bhatt DL, Hirshberg B, Mosenzon O, Wei C, et al. Impact of treatment with saxagliptin on glycemic stability and β-cell function in the SAVOR-TIMI53 study. Diabetes Obes Metab. 2015;17(5):487-94.